Those with a lot more than 11 moles on the right arm were more likely to have significantly more than 100 moles on the body, placing them at higher risk for melanoma, the researchers stated. The area above the proper elbow was especially predictive of the full total number of moles on someone’s body, based on the researchers. The number of moles on the hip and legs was strongly associated with total count also, as had been moles on men’s backs. Changes in the size, color or form of a mole may be a danger sign of melanoma. But the study only found a link between the existence of moles and melanoma risk.Kaiser Family Foundation. Copyright 2008 Advisory Panel Kaiser and Company Family members Foundation. All rights reserved.. Allos Therapeutics, Idis collaborate in named patient plan for FOLOTYN Allos Therapeutics, Inc. The U.S. Food and Medication Administration offers granted accelerated acceptance for FOLOTYN for the treating sufferers with relapsed or refractory peripheral T-cell lymphoma . This indication is based on overall response price. Clinical benefit such as improvement in progression free survival or general survival has not been demonstrated. Allos retains exceptional worldwide rights to develop and commercialize FOLOTYN in all indications.